vs
博士伦（BLCO）与Reddit, Inc.（RDDT）财务数据对比。点击上方公司名可切换其他公司
博士伦的季度营收约是Reddit, Inc.的2.1倍（$1.4B vs $663.0M），Reddit, Inc.净利率更高（30.8% vs -4.1%，领先34.9%），Reddit, Inc.同比增速更快（69.0% vs 9.8%），Reddit, Inc.自由现金流更多（$311.0M vs $60.0M），过去两年Reddit, Inc.的营收复合增速更高（53.6% vs 13.1%）
博士伦是知名眼健康产品企业，总部位于加拿大安大略省沃恩市，是全球规模最大的隐形眼镜、镜片护理产品、眼科药品、人工晶体及其他眼科手术产品供应商之一。品牌1853年由验光师约翰·鲍什与合伙人亨利·朗姆在美国纽约罗切斯特创立，曾是美国历史最悠久的持续运营企业之一，2013年被整体收购。
Reddit是美国知名的社交新闻聚合与论坛类社交媒体平台，注册用户可发布链接、文字帖、图片、视频等各类内容，其他用户可对内容进行点赞或点踩，内容按主题归类到用户创建的子板块中，获赞更高的内容会排在板块前列，热度足够的内容还将展示在全站首页。
BLCO vs RDDT — 直观对比
营收规模更大
BLCO
是对方的2.1倍
$663.0M
营收增速更快
RDDT
高出59.2%
9.8%
净利率更高
RDDT
高出34.9%
-4.1%
自由现金流更多
RDDT
多$251.0M
$60.0M
两年增速更快
RDDT
近两年复合增速
13.1%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.4B | $663.0M |
| 净利润 | $-58.0M | $204.0M |
| 毛利率 | — | 100.0% |
| 营业利润率 | 8.0% | 0.0% |
| 净利率 | -4.1% | 30.8% |
| 营收同比 | 9.8% | 69.0% |
| 净利润同比 | -1833.3% | 680.0% |
| 每股收益（稀释后） | $-0.16 | $1.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BLCORDDT
| Q1 26 | — | $663.0M | ||
| Q4 25 | $1.4B | $725.6M | ||
| Q3 25 | $1.3B | $584.9M | ||
| Q2 25 | $1.3B | $499.6M | ||
| Q1 25 | $1.1B | $392.4M | ||
| Q4 24 | $1.3B | $427.7M | ||
| Q3 24 | $1.2B | $348.4M | ||
| Q2 24 | $1.2B | $281.2M |
净利润BLCORDDT
| Q1 26 | — | $204.0M | ||
| Q4 25 | $-58.0M | $251.6M | ||
| Q3 25 | $-28.0M | $162.7M | ||
| Q2 25 | $-62.0M | $89.3M | ||
| Q1 25 | $-212.0M | $26.2M | ||
| Q4 24 | $-3.0M | $71.0M | ||
| Q3 24 | $4.0M | $29.9M | ||
| Q2 24 | $-151.0M | $-10.1M |
毛利率BLCORDDT
| Q1 26 | — | 100.0% | ||
| Q4 25 | — | 91.9% | ||
| Q3 25 | — | 91.0% | ||
| Q2 25 | — | 90.8% | ||
| Q1 25 | — | 90.5% | ||
| Q4 24 | — | 92.6% | ||
| Q3 24 | — | 90.1% | ||
| Q2 24 | — | 89.5% |
营业利润率BLCORDDT
| Q1 26 | — | 0.0% | ||
| Q4 25 | 8.0% | 31.9% | ||
| Q3 25 | 7.4% | 23.7% | ||
| Q2 25 | -0.9% | 13.6% | ||
| Q1 25 | -7.3% | 1.0% | ||
| Q4 24 | 6.8% | 12.4% | ||
| Q3 24 | 3.6% | 2.0% | ||
| Q2 24 | 2.1% | -11.0% |
净利率BLCORDDT
| Q1 26 | — | 30.8% | ||
| Q4 25 | -4.1% | 34.7% | ||
| Q3 25 | -2.2% | 27.8% | ||
| Q2 25 | -4.9% | 17.9% | ||
| Q1 25 | -18.6% | 6.7% | ||
| Q4 24 | -0.2% | 16.6% | ||
| Q3 24 | 0.3% | 8.6% | ||
| Q2 24 | -12.4% | -3.6% |
每股收益（稀释后）BLCORDDT
| Q1 26 | — | $1.01 | ||
| Q4 25 | $-0.16 | $1.24 | ||
| Q3 25 | $-0.08 | $0.80 | ||
| Q2 25 | $-0.18 | $0.45 | ||
| Q1 25 | $-0.60 | $0.13 | ||
| Q4 24 | $-0.00 | $4.76 | ||
| Q3 24 | $0.01 | $0.16 | ||
| Q2 24 | $-0.43 | $-0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $383.0M | $1.4B |
| 总债务越低越好 | $5.0B | — |
| 股东权益账面价值 | $6.4B | $3.2B |
| 总资产 | $14.0B | $3.5B |
| 负债/权益比越低杠杆越低 | 0.78× | — |
8季度趋势，按日历期对齐
现金及短期投资BLCORDDT
| Q1 26 | — | $1.4B | ||
| Q4 25 | $383.0M | $953.6M | ||
| Q3 25 | $310.0M | $911.7M | ||
| Q2 25 | $266.0M | $734.1M | ||
| Q1 25 | $202.0M | $635.7M | ||
| Q4 24 | $305.0M | $562.1M | ||
| Q3 24 | $329.0M | $515.9M | ||
| Q2 24 | $285.0M | $468.0M |
总债务BLCORDDT
| Q1 26 | — | — | ||
| Q4 25 | $5.0B | — | ||
| Q3 25 | $5.0B | — | ||
| Q2 25 | $5.0B | — | ||
| Q1 25 | $4.8B | — | ||
| Q4 24 | $4.8B | — | ||
| Q3 24 | $4.6B | — | ||
| Q2 24 | $4.6B | — |
股东权益BLCORDDT
| Q1 26 | — | $3.2B | ||
| Q4 25 | $6.4B | $2.9B | ||
| Q3 25 | $6.4B | $2.6B | ||
| Q2 25 | $6.4B | $2.4B | ||
| Q1 25 | $6.4B | $2.2B | ||
| Q4 24 | $6.5B | $2.1B | ||
| Q3 24 | $6.6B | $2.0B | ||
| Q2 24 | $6.5B | $1.9B |
总资产BLCORDDT
| Q1 26 | — | $3.5B | ||
| Q4 25 | $14.0B | $3.2B | ||
| Q3 25 | $13.8B | $2.9B | ||
| Q2 25 | $13.8B | $2.6B | ||
| Q1 25 | $13.4B | $2.4B | ||
| Q4 24 | $13.5B | $2.3B | ||
| Q3 24 | $13.5B | $2.2B | ||
| Q2 24 | $13.3B | $2.1B |
负债/权益比BLCORDDT
| Q1 26 | — | — | ||
| Q4 25 | 0.78× | — | ||
| Q3 25 | 0.77× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.76× | — | ||
| Q4 24 | 0.74× | — | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 0.71× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $136.0M | — |
| 自由现金流经营现金流 - 资本支出 | $60.0M | $311.0M |
| 自由现金流率自由现金流/营收 | 4.3% | 46.9% |
| 资本支出强度资本支出/营收 | 5.4% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-66.0M | $868.6M |
8季度趋势，按日历期对齐
经营现金流BLCORDDT
| Q1 26 | — | — | ||
| Q4 25 | $136.0M | $266.8M | ||
| Q3 25 | $137.0M | $185.2M | ||
| Q2 25 | $35.0M | $111.3M | ||
| Q1 25 | $-25.0M | $127.6M | ||
| Q4 24 | $22.0M | $90.0M | ||
| Q3 24 | $154.0M | $71.6M | ||
| Q2 24 | $15.0M | $28.4M |
自由现金流BLCORDDT
| Q1 26 | — | $311.0M | ||
| Q4 25 | $60.0M | $263.6M | ||
| Q3 25 | $63.0M | $183.1M | ||
| Q2 25 | $-54.0M | $110.8M | ||
| Q1 25 | $-135.0M | $126.6M | ||
| Q4 24 | $-70.0M | $89.2M | ||
| Q3 24 | $94.0M | $70.3M | ||
| Q2 24 | $-57.0M | $27.2M |
自由现金流率BLCORDDT
| Q1 26 | — | 46.9% | ||
| Q4 25 | 4.3% | 36.3% | ||
| Q3 25 | 4.9% | 31.3% | ||
| Q2 25 | -4.2% | 22.2% | ||
| Q1 25 | -11.9% | 32.3% | ||
| Q4 24 | -5.5% | 20.8% | ||
| Q3 24 | 7.9% | 20.2% | ||
| Q2 24 | -4.7% | 9.7% |
资本支出强度BLCORDDT
| Q1 26 | — | — | ||
| Q4 25 | 5.4% | 0.4% | ||
| Q3 25 | 5.8% | 0.4% | ||
| Q2 25 | 7.0% | 0.1% | ||
| Q1 25 | 9.7% | 0.2% | ||
| Q4 24 | 7.2% | 0.2% | ||
| Q3 24 | 5.0% | 0.4% | ||
| Q2 24 | 5.9% | 0.4% |
现金转化率BLCORDDT
| Q1 26 | — | — | ||
| Q4 25 | — | 1.06× | ||
| Q3 25 | — | 1.14× | ||
| Q2 25 | — | 1.25× | ||
| Q1 25 | — | 4.88× | ||
| Q4 24 | — | 1.27× | ||
| Q3 24 | 38.50× | 2.40× | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BLCO
| Overthe Counter Products | $489.0M | 35% |
| Pharmaceuticals | $378.0M | 27% |
| Other | $263.0M | 19% |
| Surgical | $249.0M | 18% |
| Brandedand Other Generic Products | $14.0M | 1% |
| Other Revenues | $3.0M | 0% |
| Pharmaceutical Products | $2.0M | 0% |
RDDT
暂无分部数据
